Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares,

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) rose sharply during Tuesday's session after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy.

Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne muscular dystrophy (DMD). Read more here.